Target intelligence / Profile preview

MicroRNA 122-5p (miR-122-5p)

Target
miR-122-5p
Molecular classification
MicroRNA, Non-coding RNA
01

Overview

MicroRNA 122–5p is a highly conserved, liver-specific microRNA that plays a central role in the regulation of gene expression at the post-transcriptional level. It is one of the most abundant microRNAs in adult human liver tissue—accounting for up to 72% of total hepatic miRNAs—and is essential for maintaining normal lipid metabolism. Its expression is regulated by transcription factors such as HNF4α. Functionally, miR‑122–5p modulates fatty acid metabolism, influences circadian rhythm genes, regulates cell proliferation/apoptosis pathways (including c-Abl/HDAC2), and enhances antiviral innate immunity by affecting interferon signaling. Clinically, reduced levels are associated with hepatocellular carcinoma development; conversely, it supports hepatitis C virus replication—making it both a biomarker and therapeutic target in these diseases. Circulating EV-incorporated miR‑122–5p also serves as a prognostic marker after cardiac interventions like TAVR. Therapeutic strategies targeting this molecule include antisense oligonucleotides such as miravirsen.

Other names
miR-122hsa-miR-122MIR122microRNA 122mir-122 microRNA precursor
02

Mechanism of action

Antisense inhibition of miR‑122 to reduce its activity and impact on viral replication or metabolic pathways

03

Biological functions

Post-transcriptional gene regulationRegulation of fatty acid metabolismModulation of cell proliferation and apoptosisRegulation of immune response and interferon signaling
04

Disease associations

Cancer (notably hepatocellular carcinoma)Metabolic dysfunction-associated steatotic liver disease (MASLD)Hepatitis C infectionCardiovascular disease (e.g., heart failure post-TAVR)
05

Safety considerations

Potential off-target effects due to broad regulatory roles in metabolism and cell survivalRisk of disrupting normal liver function or immune responses
06

Interacting drugs

Miravirsen (an antisense oligonucleotide targeting miR‑122; in clinical trials for hepatitis C)
07

Biomarkers

Circulating levels as a biomarker for liver injury/disease progression in MASLD and hepatitis C

Beyond the preview

Go deeper on MicroRNA 122-5p (miR-122-5p).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on MicroRNA 122-5p (miR-122-5p).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call